## BSX: Boston Scientific Corporation - XLV: Healthcare

### Executive Summary

No clear thesis: MRS_10 at 3.6%, does not meet entry criteria. Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($90.03)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 5, Bearish: 0)

**1. Is It Worth Investing in Boston Scientific (BSX) Based on Wall Street's Bullish Views?**
- Source: Finviz | 20251217T160745 | Neutral | Relevance: 100%
- This article evaluates Boston Scientific (BSX) based on Wall Street analyst recommendations and the Zacks Rank system. While BSX has a Strong Buy to Buy average brokerage recommendation, the article cautions against relying solely on these recommendations due to potential analyst bias. It suggests using the Zacks Rank, which is based on earnings estimate revisions and has a strong track record, as a more effective tool for investment decisions.

**2. UBS reiterates Buy rating on Boston Scientific stock with $140 price target**
- Source: Investing.com | 20251217T152938 | Bullish | Relevance: 100%
- UBS has reiterated its Buy rating and $140 price target for Boston Scientific (NYSE:BSX), despite a recent stock dip, citing the company's strong revenue growth and reasonable valuation. Analyst Danielle Antalffy projects upside potential, particularly from the WATCHMAN device and Electrophysiology division, which are expected to drive double-digit sales growth. Other firms like Canaccord Genuity, Leerink Partners, and TD Cowen also maintain positive outlooks, reinforcing confidence in Boston Scientific's financial performance and strategic initiatives.

**3. Gradient Investments LLC Has $22.49 Million Stock Holdings in Boston Scientific Corporation $BSX**
- Source: MarketBeat | 20251217T093030 | Bullish | Relevance: 100%
- Gradient Investments LLC increased its stake in Boston Scientific (NYSE:BSX) by 5.5% to 230,372 shares, valued at $22.49 million, during the third quarter. Boston Scientific exceeded Q3 earnings estimates with an EPS of $0.75 and revenue of $5.07 billion, and analysts currently hold a consensus "Buy" rating with a $125.15 price target. Despite insider selling, institutional ownership remains high at 89.07%.

**4. Texas Permanent School Fund Corp Reduces Stock Holdings in Boston Scientific Corporation $BSX**
- Source: MarketBeat | 20251215T130746 | Neutral | Relevance: 100%
- Texas Permanent School Fund Corp decreased its stake in Boston Scientific Corporation by 24.1% during the second quarter, selling 51,169 shares. Despite this reduction, other institutional investors like Vanguard Group Inc., State Street Corp, and Geode Capital Management LLC increased their holdings in the medical equipment provider. Several analysts have maintained "outperform" or "overweight" ratings on Boston Scientific, with a consensus "Buy" rating and an average price target of $124.43.

**5. MASTERINVEST Kapitalanlage GmbH Invests $5.23 Million in Boston Scientific Corporation $BSX**
- Source: MarketBeat | 20251215T050736 | Bullish | Relevance: 100%
- MASTERINVEST Kapitalanlage GmbH recently acquired a new stake of 48,728 shares in Boston Scientific (NYSE:BSX), valued at approximately $5.23 million. This investment comes as Boston Scientific reported strong quarterly earnings, beating expectations with $0.75 EPS and $5.07 billion revenue. Analyst sentiment remains positive, with a consensus "Buy" rating and an average price target of $124.43.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-17 | Canaccord Genui | $131 | $132 | -1% |
| 2025-12-17 | RBC Capital | $130 | $125 | +4% |
| 2025-11-21 | BTIG | $132 | $132 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-17 | Canaccord Genui | main | Buy |
| 2025-12-17 | RBC Capital | main | Outperform |
| 2025-11-21 | BTIG | reit | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 3 ($1.31M) |
| Sells | 9 ($2.57M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 43.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Blackrock Inc.: 9.8% (-1.0%)
- Vanguard Group Inc: 9.3% (+0.8%)
- FMR, LLC: 6.7% (-8.2%)
- State Street Corpora: 4.4% (-0.4%)
- JPMORGAN CHASE & CO: 3.8% (+120.8%)

### Key Risks

1. Long-term trend broken: trading 6.5% below SMA200.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Momentum building: MRS_10 improving +9.1% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.91 indicates undervaluation relative to growth. Balance sheet: $2.6B free cash flow. Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $140.1B |
| Beta | 0.67 |
| 52W Range | $85.98 - $109.50 |
| Short Interest | 1.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.91 |
| Forward P/E | 27.2 |
| Current P/E | 31.1 |
| YoY Growth | 14.3% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -5.5% to 3.6% (+9.1% in 5 days), confirming momentum buildup. Currently in lower STRENGTH zone (3.0-6.0%), cross-sectional ranking at 67th percentile. MRS_5 at 3.8% confirms short-term momentum alignment. Below SMA200 (0.94x), long-term trend not supportive. RSI neutral at 42. OFD pattern: +SUN (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 3.61% (CS: 67) | Strong |
| RSI_14 | 42.4 | Neutral |
| MACD Histogram | -0.38 | Bearish |
| vs SMA20 | 0.980x | Below |
| vs SMA50 | 0.958x | Below |
| vs SMA200 | 0.935x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $94.49
- **Stop Loss:** $90.03 (4.7% risk)
- **Target:** $98.95 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 242
- **Position Value:** $22,866.58
- **Portfolio %:** 22.87%
- **Risk Dollars:** $1,080.00
- **Risk Per Trade:** 1.08%
- **Modifiers:** L1 90% | L2 120% | Combined 1.08x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | RISK_OFF (HIGH) | 0.90x |
| L2 Sector | TREND (Zone A) | 1.20x |

*RISK_OFF regime with deteriorating conditions. VIX rising to 17.6 (+11.7% over 5 days) signals increasing anxiety, while narrow breadth at 52.6% indicates selective participation. AI infrastructure cost concerns are pressuring tech leadership, creating sector rotation challenges in a late-cycle environment.*

### Earnings

**Next:** 2026-02-04 (Est: $0.78)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.71 | $0.75 | +5.1% |
| 2025Q2 | $0.73 | $0.75 | +3.4% |
| 2025Q1 | $0.67 | $0.75 | +11.5% |
| 2024Q4 | $0.66 | $0.70 | +6.6% |

---
*RULE-based L3 | 2026-01-07 01:40 | MRS_10*